October 18, 2023
Company Description: LEVERaging RNA regulatory mechanisms to drug the undruggable with RNA-targeted therapeutics. We identify novel target RNA biology and design targeted therapeutics to increase, inhibit or restore expression/protein function. We currently have 4 programs in CNS and related disease areas, with the lead program (L5001) going into IND in 2025.
CEO/Top Company Official
Lead Product in Development
Development Phase of Primary Product
Number Of Unlicensed Products